Crossbow arms itself with $80 million for mission to cure cancer

12 July 2023

Boston, USA-based Crossbow Therapeutics, a biotech developing a new class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding round.

MPM BioImpact and Pfizer Ventures led the round, with participation from Polaris Partners, BVF Partners, Eli Lilly (NYSE: LLY), Mirae Asset Venture Investment, and Mirae Asset Capital.

The financing will allow Crossbow to advance the development of therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK